Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trialReinier C A van Linschoten, Aura A. J. van Esch, Annemarie C. de Vries et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 21
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI TrialFenna M. Jansen, Aura A. J. van Esch, Reinier C A van Linschoten et al.|Journal of Crohn s and Colitis|2023Cited by 4
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI TrialReinier C A van Linschoten, Fenna M. Jansen, R Pauwels et al.|Digestive Diseases and Sciences|2024Cited by 2
P526 A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trialR Van Linschoten, Frank Hoentjen, Fenna M. Jansen et al.|Journal of Crohn s and Colitis|2023Cited by 0